JP6343560B2 - 乳癌の判定方法 - Google Patents
乳癌の判定方法 Download PDFInfo
- Publication number
- JP6343560B2 JP6343560B2 JP2014534354A JP2014534354A JP6343560B2 JP 6343560 B2 JP6343560 B2 JP 6343560B2 JP 2014534354 A JP2014534354 A JP 2014534354A JP 2014534354 A JP2014534354 A JP 2014534354A JP 6343560 B2 JP6343560 B2 JP 6343560B2
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- cancer marker
- marker
- detecting
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010006187 Breast cancer Diseases 0.000 title claims description 239
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 239
- 238000000034 method Methods 0.000 title claims description 52
- 239000000439 tumor marker Substances 0.000 claims description 105
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 claims description 12
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 claims description 12
- 206010006223 Breast discharge Diseases 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 34
- 238000004949 mass spectrometry Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 238000003745 diagnosis Methods 0.000 description 16
- 235000004252 protein component Nutrition 0.000 description 16
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 210000002445 nipple Anatomy 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 101700006667 CA1 Proteins 0.000 description 10
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 9
- 101710139715 Superoxide dismutase [Cu-Zn] Proteins 0.000 description 9
- 102000007456 Peroxiredoxin Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 108030002458 peroxiredoxin Proteins 0.000 description 8
- 102000018757 Apolipoprotein L1 Human genes 0.000 description 7
- 108010052469 Apolipoprotein L1 Proteins 0.000 description 7
- 102100024921 Carboxypeptidase N subunit 2 Human genes 0.000 description 7
- 101710137813 Carboxypeptidase N subunit 2 Proteins 0.000 description 7
- 102100034434 Nebulin Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 108010054130 nebulin Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 102100036200 Bisphosphoglycerate mutase Human genes 0.000 description 6
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 6
- 102100031758 Extracellular matrix protein 1 Human genes 0.000 description 6
- 101710127949 Extracellular matrix protein 1 Proteins 0.000 description 6
- 101710157404 Flavin reductase Proteins 0.000 description 6
- 102100027944 Flavin reductase (NADPH) Human genes 0.000 description 6
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 6
- 102100036202 Serum amyloid P-component Human genes 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010028777 Complement C8 Proteins 0.000 description 5
- 102000008915 Complement component C8 alpha chains Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000004492 nuclear pore Anatomy 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 4
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 4
- 102000007592 Apolipoproteins Human genes 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 229910017518 Cu Zn Inorganic materials 0.000 description 3
- 229910017752 Cu-Zn Inorganic materials 0.000 description 3
- 229910017943 Cu—Zn Inorganic materials 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710104492 NUP210 Proteins 0.000 description 1
- 102100035570 Nuclear pore membrane glycoprotein 210 Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005319 nano flow HPLC Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/30—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving catalase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/365—Breast disorders, e.g. mastalgia, mastitits, Paget's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
(1)カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C−I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu−Zn](超酸化物不均化酵素[Cu−Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカー。
(2)試料中のカルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C−I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu−Zn](超酸化物不均化酵素[Cu−Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から任意に選択される1つ以上の乳癌マーカーを検出し、その結果に基づいて判定する、乳癌の判定方法。
(3)カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C−I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu−Zn](超酸化物不均化酵素[Cu−Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカーを検出する試薬を含む、乳癌を判定するために乳癌マーカーを検出するためのキット。
(1)試料の前処理
乳癌患者(11名)から採取したそれぞれの乳頭分泌液(数μL)を、100μL のサンプル保存液(50 mM 炭酸水素アンモニウムと0.02% アジ化ナトリウムを含有する水溶液)に加え、4℃、5分間 18,000 x g で遠心した。上澄みを分取後、280 nm の波長の紫外線を用いた紫外吸収法によりタンパク質濃度を求め、50 mM 炭酸水素アンモニウム水溶液を用いてタンパク質濃度が 0.5 mg/mL となるように調製した。45 mM ジチオトレイトール水溶液を 1.41μL 加えて還元し、タンパク質を変性させるためトリフルオロエタノールを 50% になるよう加え、60 ℃、1時間加熱した。加熱後室温に戻し、100 mM のヨードアセトアミド水溶液を 1.41μL 加えて室温暗環境下において1時間アルキル化を行った。次いで、アルキル化産物から10μLを分取し、90μLの50 mM 炭酸水素アンモニウム水溶液を加えて、トリフルオロエタノールの割合が 5%になるように調整した。更に、100ng/μLのトリプシン(マススペクトロメトリーグレード、Promega Corporation, Madison, WI, USA)の溶液 1.2μL(タンパク質重量の 1/20量のトリプシン含有)を加え 37 ℃ で一晩インキュベートした。得られたトリプシン消化産物(タンパク質換算で約 350 fmol/μL)について、以下の方法で二次元ナノLC−ESI−MS/MS測定を行った。
上記(1)で得られたトリプシン消化産物のうち40μLを、二次元 Nano HPLC system (UltiMate 3000; Thermo Fisher Scientific Inc. (Dionex), Waltham, MA, USA) に装着した Acclaim PA2, 300μm i.d. x 15 cm 逆相カラム (Thermo Fisher Scientific Inc. (Dionex), Waltham, MA, USA) を用いて A 溶媒 20 mM ギ酸アンモニウム水溶液, pH 10.0、B 溶媒 アセトニトリルを用い、75分のグラジエント(12〜95% の B 溶媒)で分離し 26 個の画分を得た。それらの画分を 70 ℃ で4時間加熱して溶媒を蒸発させた。次いで各々の画分に 0.1% トリフルオロ酢酸水溶液を 30μL 加えて、分離した成分を溶解させた。次いで、得られた各画分溶液の各全量を、それぞれ L−column Micro L2−C18, 75μm i.d. x 15 cm 逆相カラム((財)化学物質評価研究機構製)を用いて A 溶媒 0.1% ギ酸水溶液、B 溶媒 アセトニトリル/0.1% ギ酸を用い、45分のグラジエント(2〜95% の B 溶媒)で分離し、連続的にナノESIイオン源を装着したESI−イオントラップ型質量分析計 (HCTultra; Bruker Daltonik GmbH, Bremen, Germany)でデータ依存的スキャンを用いてオンライン分析した。各試料について、2回のランを行った。
i)LC 条件
(一次元目)
HPLCカラム:Acclaim PA2, 300μm i.d. x 15 cm 逆相カラム (Thermo Fisher Scientific Inc. (Dionex) 製)
流速:6.0μL/分
A 溶媒:20 mM ギ酸アンモニウム水溶液, pH 10.0
B 溶媒:アセトニトリル
溶出: 0分→19 分:12% から 20% B 溶媒までリニアグラジエント、
19 分→29 分:48% B 溶媒までリニアグラジエント、
29 分→34 分:95% B 溶媒で洗浄、
34 分→75 分:2% B 溶媒で平衡化。
(なお、溶出開始後すぐにB溶媒の濃度を上げたので、溶出開始後ほとんど0分で、溶出液のB溶媒の濃度は12%になっている。)
カラム温度:35 ℃
注入量:40μL
分画数:26
HPLCカラム:L−column Micro L2−C18, 75μm i.d. x 15 cm 逆相カラム((財)化学物質評価研究機構製)
流速:300 nL/分
A 溶媒:0.1% ギ酸水溶液, pH 2.0
B 溶媒:アセトニトリル/0.1% ギ酸
溶出: 0分→1 分:8% B 溶媒までリニアグラジエント、
1 分→20 分:20% B 溶媒までリニアグラジエント、
20 分→25 分:35% B 溶媒までリニアグラジエント、
25 分→30 分:95% B 溶媒で洗浄、
30 分→45 分:2% B 溶媒で平衡化。
カラム温度:室温
注入量:30μL
イオン化法:エレクトロスプレーイオン化法 (electrospray ionization 法、ESI 法)
測定イオン:正イオン
スプレー電圧:1200V
ドライガス:窒素(4 L/min)
イオン源温度:160 ℃
走査範囲:m/z 300 〜 1,500(MS/MS 測定時:m/z 50 〜 2,200)
プリカーサーイオン選択数:4 イオン/マススペクトル
最小限のプリカーサーイオン強度:50,000 カウント
プリカーサーイオン選択排除時間:30 s
プリカーサーイオン排除価数:1
タンパク質サーチエンジン:Mascot (Matrix Science Ltd., London,UK)
タンパク質サーチ手法:MS/MS Ion Search
タンパク質データベース:Swiss−Prot
タンパク質サーチ時動物種分類:Homo sapiens (human)
タンパク質サーチ時翻訳後修飾設定:Carbamidomethyl (システイン残基修飾)
トリプシン未切断部位許容回数:1
プリカーサーイオン質量許容値:±0.5 Da
プロダクトイオン質量許容値:±1 Da
同定タンパク質解析ソフトウェア:Scaffold(Proteome Software,Inc., Portland, OR, USA)
二次元ナノLC−ESI−MS/MS測定によって、乳癌患者由来試料から350種、非乳癌者由来試料から479種、総計575種のタンパク質成分が検出された。この分析では、特許文献2に記載されたペルオキシレドキシン1は乳癌患者試料及び非乳癌者試料の両方から検出され、更に乳癌患者に特異的な検出ではなかったことを、付記しておく。
上記(3)の結果を基に、
(i)分析を行った乳癌患者11名中の、各タンパク質成分が試料中に検出された乳癌患者数(n1)の割合(比率A)、
(ii)分析を行った非乳癌者15名中の、各タンパク質成分が試料中に検出された非乳癌者数(n2)の割合(比率B)、及び
(iii)比率A/比率B(比率C)
を求めた。
Claims (7)
- 炭酸脱水酵素2(カルボニックアンヒドラーゼ2)である、乳癌の存否を判定するための乳癌マーカー。
- 乳癌の存否を判定するためのデータを得るために、試料中の請求項1に記載の乳癌マーカーを検出することを特徴とする方法。
- 試料が乳頭分泌液である、請求項2に記載の方法。
- 試料が血清、血漿、又は全血である、請求項2に記載の方法。
- 請求項1に記載の乳癌マーカーを検出する試薬を含む、乳癌の存否を判定するために該乳癌マーカーを検出するためのキット。
- 乳癌マーカーを検出する試薬が乳癌マーカーに親和性を有する物質を含むものである、請求項5に記載のキット。
- 乳癌マーカーに親和性を有する物質が抗体である、請求項6に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012194804 | 2012-09-05 | ||
JP2012194804 | 2012-09-05 | ||
PCT/JP2013/073594 WO2014038524A1 (ja) | 2012-09-05 | 2013-09-03 | 乳癌の判定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2014038524A1 JPWO2014038524A1 (ja) | 2016-08-08 |
JP6343560B2 true JP6343560B2 (ja) | 2018-06-13 |
Family
ID=50237133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014534354A Expired - Fee Related JP6343560B2 (ja) | 2012-09-05 | 2013-09-03 | 乳癌の判定方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150203892A1 (ja) |
EP (1) | EP2894477A4 (ja) |
JP (1) | JP6343560B2 (ja) |
CN (1) | CN104583777A (ja) |
WO (1) | WO2014038524A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016074084A1 (en) * | 2014-11-12 | 2016-05-19 | Consortium For Clinical Diagnostics | Predictive biomarker(s) of treatment with erb antibodies |
WO2017181163A2 (en) * | 2016-04-16 | 2017-10-19 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
CN108132349A (zh) * | 2016-11-30 | 2018-06-08 | 北京大学 | 一种用于癫痫预后评估的生物标志物 |
EP3816628B1 (en) | 2018-06-26 | 2023-08-16 | FUJIFILM Corporation | Pancreatic cancer determination marker |
WO2021095824A1 (ja) | 2019-11-15 | 2021-05-20 | 富士フイルム和光純薬株式会社 | 大腸癌の診断を補助する方法、キット及びバイオマーカー |
JPWO2023181451A1 (ja) | 2022-03-23 | 2023-09-28 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO114835B1 (ro) * | 1997-03-17 | 1999-07-30 | Ioan Puşcaş | Metodă rapidă de diagnostic al cancerelor |
US6610484B1 (en) * | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
US6369210B1 (en) * | 1999-06-30 | 2002-04-09 | Millennium Pharmaceuticals, Inc. | 22012, human carboxypeptidase |
US6964849B2 (en) * | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
AU2002316251A1 (en) * | 2001-06-18 | 2003-01-02 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
AU2003217774A1 (en) * | 2002-02-28 | 2003-09-16 | Georgetown University | Method and composition for detection and treatment of breast cancer |
JP2005537790A (ja) * | 2002-09-05 | 2005-12-15 | ガーバン インスティテュート オブ メディカル リサーチ | 新規診断および治療方法およびそのための試薬類 |
CA2567987A1 (en) * | 2004-06-18 | 2005-12-29 | Gabriele Pestlin | Use of protein pdx1 as a marker for breast cancer |
GB0616045D0 (en) * | 2006-08-11 | 2006-09-20 | Univ Bristol | Blood cell separation |
CN101594886A (zh) * | 2006-08-29 | 2009-12-02 | 分子制药洞察公司 | 偶合到用于成像表达肽酶的组织和器官的肽酶结合部分的放射影像部分 |
WO2008074131A1 (en) * | 2006-12-20 | 2008-06-26 | Mcmaster University | Skin and salivary tests for the detection of sensitivity to oxidative stress based therapies |
US8097423B2 (en) * | 2007-07-30 | 2012-01-17 | Institute Of Virology | MN/CA IX and breast cancer therapy |
WO2009055820A2 (en) * | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Salivary protein biomarkers for human oral cancer |
JP6028960B2 (ja) * | 2009-07-14 | 2016-11-24 | 国立研究開発法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
JP2015155795A (ja) * | 2012-05-21 | 2015-08-27 | 東レ株式会社 | 癌の検出方法 |
-
2013
- 2013-09-03 WO PCT/JP2013/073594 patent/WO2014038524A1/ja active Application Filing
- 2013-09-03 CN CN201380041482.9A patent/CN104583777A/zh active Pending
- 2013-09-03 EP EP13835821.3A patent/EP2894477A4/en not_active Withdrawn
- 2013-09-03 JP JP2014534354A patent/JP6343560B2/ja not_active Expired - Fee Related
- 2013-09-03 US US14/416,984 patent/US20150203892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2894477A1 (en) | 2015-07-15 |
WO2014038524A1 (ja) | 2014-03-13 |
US20150203892A1 (en) | 2015-07-23 |
JPWO2014038524A1 (ja) | 2016-08-08 |
EP2894477A4 (en) | 2016-07-20 |
CN104583777A (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6343560B2 (ja) | 乳癌の判定方法 | |
US10184943B2 (en) | Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same | |
AU2020202066A1 (en) | Methods and compositions for detecting pancreatic cancer | |
AU2013210776B2 (en) | Biomarkers for gastric cancer and uses thereof | |
US8623667B2 (en) | Method for diagnosing cancer using lectin | |
KR20200020927A (ko) | 대장암을 검출하기 위한 바이오마커 | |
JP2015105951A (ja) | 血液由来の癌診断用ペプチドマーカー及びそれを用いた癌診断方法 | |
JP6336957B2 (ja) | 乳癌の判定法 | |
EP4414708A1 (en) | Biomarker for cancer diagnosis and use thereof | |
JP5867834B2 (ja) | 肺癌マーカー補体C3dg分子及び肺癌マーカーの分析方法 | |
KR101219516B1 (ko) | 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 | |
JP2015184168A (ja) | 大腸癌マーカー及び大腸癌検出方法 | |
JP5429725B1 (ja) | 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット | |
JP2017090102A (ja) | 浸潤性乳癌の判定法 | |
JP2017090103A (ja) | 非浸潤性乳癌の判定法 | |
JP6145650B2 (ja) | 卵巣癌マーカー及び卵巣癌検出方法 | |
US20130157291A1 (en) | DIAGNOSTIC MARKER FOR LUNG CANCER COMPRISING HPaR AS ACTIVE INGREDIENT | |
JP7336097B2 (ja) | 乳がんに関するペプチドマーカー | |
EP4257601A1 (en) | Breast cancer diagnosis assistance method and breast cancer test kit | |
JP2017198509A (ja) | 大腸癌マーカー | |
KR101819939B1 (ko) | 유방암 진단용 단백질 마커 베타-투 마이크로글로불린 및 이를 검출하는 방법 | |
KR101912377B1 (ko) | 폐암감별진단용 바이오마커 및 이를 이용한 폐암감별진단용 정보제공 방법 | |
You | Discovery of novel potential protein diagnostic biomarkers for Prostate Cancer in serum and tears | |
WO2016208041A1 (ja) | 卵巣癌マーカー及び卵巣癌検出方法 | |
JP2018163071A (ja) | 関節リウマチに関するペプチドマーカー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160818 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171010 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180201 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180521 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6343560 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |